Sign in

CIK 0001393434

  • Large accelerated filer

OCULAR THERAPEUTIX, INC

Sign in to watch
Ticker
OCUL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 781-357-4000
Business address
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
Former names
I-THERAPEUTIX INC
  1. 4 Planned sale See Remarks sold 21,156 shares at $8.20 ($173,479)
  2. 4 Planned sale Chief Development Officer sold 2,967 shares at $8.20 ($24,329)
  3. 4 Planned sale Chief Scientific Officer sold 3,018 shares at $8.20 ($24,748)
  4. 4 Planned sale Chief Strategy Officer sold 1,858 shares at $8.20 ($15,236)
  5. 4 Gift See Remarks gave 394,696 shares (gift)
  6. 4 Planned sale See Remarks sold 20,056 shares at $8.28 ($166,064)
  7. 4 Planned sale Chief Development Officer sold 2,810 shares at $8.28 ($23,267)
  8. 4 Planned sale Chief Scientific Officer sold 3,057 shares at $8.28 ($25,312)
  9. 4 Planned sale Chief Strategy Officer sold 1,759 shares at $8.28 ($14,565)
  10. 4 Planned sale Chief Medical Officer sold 3,510 shares at $7.74 ($27,167)
  11. 4 Open-market buy Director bought 60,229 shares at $7.66 ($461,354)
  12. 4 Open-market sale Chief Operating Officer sold 11,446 shares at $9.04 ($103,472)
  13. 4 Planned sale Chief Strategy Officer sold 10,348 shares at $9.04 ($93,546)
  14. 4 Planned sale See Remarks sold 124,882 shares at $9.04 ($1,128,933)
  15. 4 Planned sale Chief Medical Officer sold 7,863 shares at $9.04 ($71,082)
  16. 4 Open-market sale Chief Operating Officer sold 11,490 shares at an average $8.82 ($101,398)
  17. 4 Grant or award Global CCO acquired 136,000 shares (grant or award)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 2 of 18 · 354 filings